@Article{duepublico_mods_00082282, author = {Moraitis, Alexandros and Jentzen, Walter and Reiter, Gloria and Schmitz, Jochen and P{\"o}ppel, Thorsten Dirk and Weber, Manuel and Herrmann, Ken and Fendler, Wolfgang Peter and Fragoso Costa, Pedro and Bockisch, Andreas and Kersting, David}, title = {Biodistribution and radiation dosimetry of {\textonesuperior}{\texttwosuperior}⁴I-mIBG in adult patients with neural crest tumours and extrapolation to paediatric models}, year = {2024}, month = {Jan}, day = {03}, keywords = {Dosimetry; 124I-mIBG; PET; Effective dose; Neural crest tumour}, abstract = {Aim: Positron emission tomography (PET) using 124I-mIBG has been established for imaging and pretherapeutic dosimetry. Here, we report the first systematic analysis of the biodistribution and radiation dosimetry of 124I-mIBG in patients with neural crest tumours and project the results to paediatric patient models. Methods: Adult patients with neural crest tumours who underwent sequential 124I-mIBG PET were included in this retrospective single-center analysis. PET data were acquired 4, 24, 48, and/or 120 h after administration of a mean of 43 MBq 124I-mIBG. Whole-body counting and blood sampling were performed at 2, 4, 24, 48 and 120 h after administration. Absorbed organ dose and effective dose coefficients were estimated in OLINDA/EXM 2.2 according to the MIRD formalism. Extrapolation to paediatric models was performed based on mass-fraction scaling of the organ-specific residence times. Biodistribution data for adults were also projected to 123I-mIBG and 131I-mIBG. Results: Twenty-one patients (11 females, 10 males) were evaluated. For adults, the organs exposed to the highest dose per unit administered activity were urinary bladder (1.54{\thinspace}{\textpm}{\thinspace}0.40 mGy/MBq), salivary glands (0.77{\thinspace}{\textpm}{\thinspace}0.28 mGy/MBq) and liver (0.65{\thinspace}{\textpm}{\thinspace}0.22 mGy/MBq). Mean effective dose coefficient for adults was 0.25{\thinspace}{\textpm}{\thinspace}0.04 mSv/MBq (male: 0.24{\thinspace}{\textpm}{\thinspace}0.03 mSv/MBq, female: 0.26{\thinspace}{\textpm}{\thinspace}0.06 mSv/MBq), and increased gradually to 0.29, 0.44, 0.69, 1.21, and 2.94 mSv/MBq for the 15-, 10-, 5-, 1-years-old, and newborn paediatric reference patients. Projected mean effective dose coefficients for 123I-mIBG and 131I-mIBG for adults were 0.014{\thinspace}{\textpm}{\thinspace}0.002 mSv/MBq and 0.18{\thinspace}{\textpm}{\thinspace}0.04 mSv/MBq, respectively. Conclusion: PET-based derived radiation dosimetry data for 124I-mIBG from this study agreed well with historical projected data from ICRP 53. The effective dose coefficients presented here may aid in guidance for establishing weight-based activity administration protocols.}, note = {<p>Open Access funding enabled and organized by Projekt DEAL.</p> <p>The publication of this article was supported by the Publication Fund of the University of Duisburg-Essen.</p>}, note = {<p>Moraitis, A., Jentzen, W., Reiter, G. <em>et al.</em> Biodistribution and radiation dosimetry of <sup>124</sup>I-mIBG in adult patients with neural crest tumours and extrapolation to paediatric models. <em>EJNMMI Phys</em><strong> 11</strong>, 3 (2024). <a href="10.1186/s40658-023-00604-0">https://doi.org/10.1186/s40658-023-00604-0</a></p> <p>Published 03 January 2024</p>}, note = {Verlagsversion / Version of Record}, doi = {10.1186/s40658-023-00604-0}, url = {https://duepublico2.uni-due.de/receive/duepublico_mods_00082282}, url = {https://doi.org/10.1186/s40658-023-00604-0}, file = {:https://duepublico2.uni-due.de/servlets/MCRFileNodeServlet/duepublico_derivate_00082431/s40658-023-00604-0.pdf:PDF}, language = {en} }